Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder
The DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index.
Abstract
The synthesis and structure-activity relationship of a novel series of compounds with combined effects on 5-HT(3A) and 5-HT(1A) receptors and on the serotonin (5-HT) transporter (SERT) are described. Compound 5m (Lu AA21004) was the lead compound, displaying high affinity for recombinant human 5-HT(1A) (K(i) = 15 nM), 5-HT(1B) (K(i) = 33 nM), 5-HT(3A) (K(i) = 3.7 nM), 5-HT(7) (K(i) = 19 nM), and noradrenergic β(1) (K(i) = 46 nM) receptors, and SERT (K(i) = 1.6 nM). Compound 5m displayed antagonistic properties at 5-HT(3A) and 5-HT(7) receptors, partial agonist properties at 5-HT(1B) receptors, agonistic properties at 5-HT(1A) receptors, and potent inhibition of SERT. In conscious rats, 5m significantly increased extracellular 5-HT levels in the brain after acute and 3 days of treatment. Following the 3-day treatment (5 or 10 (mg/kg)/day) SERT occupancies were only 43% and 57%, respectively. These characteristics indicate that 5m is a novel multimodal serotonergic compound, and 5m is currently in clinical development for major depressive disorder.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The in vivo nonclinical studies in rodents have demonstrated that vortioxetine modulates serotonergic, noradrenergic, dopaminergic, cholinergic, histaminergic, and glutamatergic neurotransmission, affecting the levels of neurotransmitters involved in cognitive processes (Bang-Andersen et al, 2011; Mork et al, 2012, 2013; Pehrson et al, 2013; Pehrson and Sanchez, 2014; Wallace et al, 2014).”
From A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder (2015) · cites this paper as Bang-Andersen et al, 2011
In the citing paper
“The antidepressant vortioxetine, developed by Lundbeck and Takeda and approved in 2013, is a 5-HT 3 , 5-HT 7 and 5-HT 1D receptor antagonist, a 5-HT 1B receptor partial agonist, a 5-HT 1A receptor agonist and an inhibitor of the 5-HT transporter (Bang-Andersen et al., 2011) with a good tolerability and long-term safety profile and no evidence of sexual dysfunction as a side effect.”
From Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders (2019) · cites this paper as Bang-Andersen et al., 2011
In the citing paper
“Vortioxetine (Lu AA21004) is an antidepressant that acts as an antagonist of the 5-HT3 and 5-HT7 serotonin receptors, partial agonist of the 5-HT1B serotonin receptor, agonist of the 5-HT1A receptor, and inhibits the serotonin transporter [88].”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [88]
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Are the Dorsal and Ventral Hippocampus Functionally Distinct Structures?
Fanselow, M. S., & Dong, H.-W. (2010) · Neuron · doi:10.1016/j.neuron.2009.11.031 · Cited by 3,358
Drevets, W. C., Price, J. L., & Furey, M. L. (2008) · Brain Structure and Function · doi:10.1007/s00429-008-0189-x · Cited by 2,241
Evidence-based health policy—lessons from the Global Burden of Disease Study
Murray, C. J. L., & Lopez, A. D. (1996) · Science · doi:10.1126/science.274.5288.740 · Cited by 2,178
Designed Multiple Ligands. An Emerging Drug Discovery Paradigm
Morphy, R., & Rankovic, Z. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058225d · Cited by 1,209
A Simple Catalytic Method for the Conversion of Aryl Bromides to Arylamines
Guram, A. S., Rennels, R. A., & Buchwald, S. L. (1995) · Angewandte Chemie International Edition in English · doi:10.1002/anie.199513481 · Cited by 1,070
Louie, J., & Hartwig, J. F. (1995) · Tetrahedron Letters · doi:10.1016/0040-4039(95)00605-c · Cited by 914
Is there a role for 5-HT1A agonists in the treatment of depression?
Blier, P., & Ward, N. M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01643-8 · Cited by 529
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517
Research works printed but not linked: 3
- Lenox R. H., 2002, Neuropsychopharmacology: The Fifth Generation of Progress: An Official Publication of the American College of Neuropsychopharmacology, 1139
- Moore N. A., 2008, Neuropsychopharmacology, 18, S321, 10.1016/s0924-977x(08)70440-1 · DOI
- Brunello N., 2003, Int. Clin. Psychopharmacol., 18, 191, 10.1097/01.yic.0000073880.93678.68 · doi:10.1097/01.yic.0000073880.93678.68 · Paper page
Cited by
Items 301–400 of 628
Guan, S., Zou, Y., Jia, B., Wu, L., Yang, Z., Yuan, F., & Zhang, L. (2018) · Journal of Separation Science · doi:10.1002/jssc.201800607 · Cited by 8
Anhedonia as a basic syndrome and a target for treatment for depressive disorder
Mazo, G. E., & Kibitov, A. O. (2019) · V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY · doi:10.31363/2313-7053-2019-3-10-18 · Cited by 10
Witten, L. M., Bang‐Andersen, B., Nielsen, S. M., Miller, S., Christoffersen, C. T., Stensbøl, T. B., Brennum, L. T., & Arnt, J. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.11.029 · Cited by 8
Self-citationYi, Y., Ren, G., Zheng, M. Y., Zhao, D., Li, N., Chen, X., & Lu, Y. (2019) · Journal of Chromatography B · doi:10.1016/j.jchromb.2019.121955 · Cited by 8
Lombardozzi, G., Kotzalidis, G. D., Filippis, S. D., Matrone, M., Amici, E., Trovini, G., Perrini, F., Giovanni, A. D., & Giovanetti, V. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220310122849 · Cited by 7
Antistress and antidepressant properties of dapoxetine and vortioxetine
Ratajczak, P., Kus, K., Zielińska‐Przyjemska, M., Skórczewska, B., Zaprutko, T., Kopciuch, D., Paczkowska, A., & Nowakowska, E. (2020) · Acta Neurobiologiae Experimentalis · doi:10.21307/ane-2020-020 · Cited by 7
“Our results corroborate with results of the study by Bang‑Andersen et al. (2011), who proved VOR administered subcutaneously to rats at the doses of 2.5, 5, and 10 mg/kg to have an antidepressant effect (especially through 5HT1B, 5‑HT3, and 5‑HT7 receptors).”
ResultInfluentialSmajdor, J., Zambrzycki, M., Paczosa‐Bator, B., & Piech, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314555 · Cited by 7
Ma, D., Li, G., & Wang, X. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s103173 · Cited by 9
“14,15 The current recommend dosage of vortioxetine for the treatment of MDD is 5–20 mg/day, 15 and 10 mg/day is recommended as the starting dose.”
He, Y., Gan, X., Li, X., Wang, T., Li, J., Lei, T., Huang, Y., Liu, R., Chen, F., Teng, T., et al. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05221-w · Cited by 8
“Vortioxetine was selected for its multimodal mechanism of action [28].”
BackgroundSouza, E. S. D., Hegde, S., Nizam, A., & Lakshmaiah, V. V. (2025) · Asian Journal of Organic Chemistry · doi:10.1002/ajoc.202500266 · Cited by 6
Vortioxetine treatment decreases cocaine-induced locomotor sensitization in rats
Barbosa-Méndez, S., Pérez‐Sánchez, G., & Salazar‐Juárez, A. (2022) · Physiology & Behavior · doi:10.1016/j.physbeh.2022.113989 · Cited by 6
Sahoo, S., & Rit, A. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202504156 · Cited by 6
Laursen, B., Bundgaard, C. H., Graversen, C., Grupe, M., Sánchez, C., Leiser, S. C., Sørensen, H. B. D., Drewes, A. M., & Bastlund, J. F. (2017) · Brain Research · doi:10.1016/j.brainres.2017.03.024 · Cited by 6
Snapshot of Antidepressants at Work: The Structure of Neurotransmitter Transporter Proteins
Cuboni, S., & Hausch, F. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201310567 · Cited by 7
Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial
Mills, N. T., Sampson, E., Fourrier, C., & Baune, B. T. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa092 · Cited by 6
Kotzalidis, G. D., Lombardozzi, G., Matrone, M., Amici, E., Perrini, F., Cuomo, I., & Filippis, S. D. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210113150123 · Cited by 6
“It is a 5-HT3, 5-HT7 and 5-HT1D receptor antagonist, a 5-HT1B partial agonist, a 5-HT1A agonist and an inhibitor of the 5-HT transporter [13].”
New Somatic Treatments for Child and Adolescent Depression
Cullen, K. R., Padilla, L. E., Papke, V. N., & Klimes-Dougan, B. (2019) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-019-00194-8 · Cited by 5
Multimodal serotonergic antidepressants
Danilov, D. S. (2017) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro201711791103-111 · Cited by 6
García‐Alberca, J. M., de la Guía, P., Gris, E., Mendoza, S., de la Rica, M. L., Barbancho, M. Á., Lara, J. P., & Blanco‐Reina, E. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14090918 · Cited by 7
The Discriminative Stimulus Properties of Drugs Used to Treat Depression and Anxiety
Prus, A. J., & Porter, J. H. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_27 · Cited by 5
Jumping from Fragment to Drug via Smart Scaffolds
Farahani, M. D., França, T. C. C., Alapour, S., Shahout, F., Boulon, R., Iddir, M., Maddalena, M., Ayotte, Y., & LaPlante, S. R. (2022) · ChemMedChem · doi:10.1002/cmdc.202200092 · Cited by 5
Nayek, N., & Brahmachari, G. (2022) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202201343 · Cited by 5
Gao, S., Xie, X., Fan, L., & Zhang, D. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12214 · Cited by 5
“Vortioxetine exerts its pharmacological activity in vivo via 5‑hydroxytryptamine type 3 (5‑HT3) receptor, 5‑HT7 receptor and 5‑hydroxytryptamine (serotonin) receptor 1D (5‑HT1D) antagonism, 5‑HT1B receptor partial agonism, 5‑HT1A receptor agonism and 5‑HT transporter inhibition (7,8).”
Hot and cold cognition in major depressive disorder
Robinson, O. J., Roiser, J. P., & Sahakian, B. J. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781139860567.007 · Cited by 7
François, C., Nielsen, R. Z., Danchenko, N., Williams, V. S. L., & Lançon, C. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1299701 · Cited by 5
Wang, J., Liu, X., Feng, C., Quan, B., & Fu, H.-R. (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2017.1397700 · Cited by 5
“Additionally, it is also the 5-HT1B receptor partial agonist, 5-HT1D receptor agonist, and an inhibitor of the 5-HT transporter (Bang-Andersen et al., 2011; Westrich et al., 2012).”
BackgroundRetractedEnvironmentally Benign Large-Scale Synthesis of a Precursor to Vortioxetine
Gallos, J. K., Zisopoulou, S. A., Pafili, A., Gkizis, P. L., Andreou, T., Koftis, T. V., Lithadioti, A., & Neokosmidis, E. (2020) · Synthesis · doi:10.1055/s-0040-1707823 · Cited by 5
Tırıs, G., Alver, C., & Erk, N. (2020) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-020-00135-w · Cited by 6
Ni, Y.-N., Du, X.-L., Wang, T., Chen, Y.-B., Xu, X.-Q., Zhao, S., Li, J.-Q., & Wang, G. (2021) · Pharmaceutical Fronts · doi:10.1055/s-0041-1740049 · Cited by 2
Long-Term Adaptive Changes Induced by Antidepressants: From Conventional to Novel Therapies
Mnie‐Filali, O., Abrial, E., Lambás‐Señas, L., & Haddjeri, N. (2013) · InTech eBooks · doi:10.5772/54553 · Cited by 6
“[87] Bang-Andersen B, Ruhland T, Jorgensen M, Smith G, Frederiksen K, Jensen KG, et al.”
BackgroundRestless Legs Syndrome Related to Vortioxetine: A Case Report
Romigi, A., Vitrani, G., Caccamo, M., & Centonze, D. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001092 · Cited by 5
Shui, Y., Ge, X., Cao, C., Wang, J., Hu, J., & Liu, Y. (2025) · BMC Biology · doi:10.1186/s12915-025-02407-4 · Cited by 4
“Similarly, DB09068 (Vortioxetine), a multimodal serotonin modulator [57], showed 4 true positives and 7 true negatives, with only one FP and three FNs.”
Мультимодальный механизм действия препарата маритупирдин и спектр потенциальных клинических эффектов
Анатольевна, С. Е., Иващенко, А. В., Ivaschenko, A. A., Ivashchenko, I. A., & Мосолова, Е. С. (2026) · Современная терапия психических расстройств · doi:10.48612/psyph/enbu-rbm4-r5bu · Cited by 4
Zajdel, P., Masurier, N., Canale, V., Verdié, P., Amblard, M., Pawłowski, M., Martínez, J., & Subra, G. (2012) · Tetrahedron Letters · doi:10.1016/j.tetlet.2012.12.036 · Cited by 4
Subhas, N., Ang, J. K., Tan, K., & Ahmad, S. N. A. (2022) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2022.2149415 · Cited by 5
“This medication has precognitive effects that promote neuroplasticity of the hippocampus and modulate both glutamatergic and serotonergic neurotransmission, thus improving the neurocognitive dysfunction (Bang-Andersen et al., 2011; Dale et al., 2014; Pehrson & Sanchez, 2014).”
BackgroundYamalı, C., Nenni, M., Sakarya, M. T., & Kaplan, H. A. (2024) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575319878240612070850 · Cited by 4
Intramolecular [2+2] Cycloadditions of α‐Heteroatom Substituted γ,δ‐Unsaturated Ketenes
Liu, T., Lin, Z., & Yoo, W. (2024) · Asian Journal of Organic Chemistry · doi:10.1002/ajoc.202400302 · Cited by 4
Levomilnacipran and vortioxetine: Review of new pharmacotherapies for major depressive disorder
Liu, M. T. (2015) · World Journal of Pharmacology · doi:10.5497/wjp.v4.i1.17 · Cited by 4
Rajathei, D. M., Parthasarathy, S., & Selvaraj, S. (2018) · Current Computer - Aided Drug Design · doi:10.2174/1573409914666181011144810 · Cited by 4
Cognitive Dysfunction in the Workplace: Focus on Depression
Lam, R. W. M., & Persad, C. C. (2019) · Integrating psychiatry and primary care · doi:10.1007/978-3-030-04266-0_7 · Cited by 4
Effective Vortioxetine Dose Varies with Extent of Antidepressant Use Across Countries
Tegin, C., Tegin, G., & El‐Mallakh, R. S. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4559 · Cited by 4
Medication for Depression: Monoamine Enhancers and Esketamine (Antidepressants)
Park, S., & Shen, W. W. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_133-1 · Cited by 5
Eliaçık, S., & Kaya, A. E. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1398417 · Cited by 4
“These mechanisms of action of Vo support its efficacy in neuroplasticity (11, 20–22).”
BackgroundThe efficacy of vortioxetine for the treatment of major depressive disorder
Dhir, A., & Sarvaiya, J. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.987131 · Cited by 4
“6 nM when assessed in vitro using recombinant human serotonin transporters [7].”
MethodDu, R., Xu, J., Li, J., Zhang, L., Ning, L., & Li, S. (2020) · New Journal of Chemistry · doi:10.1039/d0nj05052k · Cited by 4
Cumbo, E., & Migliore, D. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251340084 · Cited by 4
Huang, C.-J., Yang, Y., Wang, X., & Liao, C. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03086 · Cited by 4
Bang‐Andersen, B., Olsen, C. K., & Sánchez, C. (2016) · Wiley eBooks · doi:10.1002/9783527800315.ch9 · Cited by 4
Self-citationThe Structure-property Relationships of GPCR-targeted Drugs Approved between 2011 and 2021
Choi, K. (2022) · Current Medicinal Chemistry · doi:10.2174/1573399819666221102113217 · Cited by 3
Tangen, Ä., Veldman, E. R., Svensson, J. E., Tiger, M., Nord, M., Sorjonen, K., Andersson, M., Plavén‐Sigray, P., Varrone, A., Halldin, C., et al. (2022) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac084 · Cited by 3
“Studies on vortioxetine, a serotonin reuptake inhibitor with 5-HT 1B agonist activity (Bang-Andersen et al., 2011; Yang et al., 2019), have indicated beneficial effects on psychomotor speed and executive control compared with selective serotonin reuptake inhibitors in MDD patients (Bennabi et al.,…”
5-Hydroxytryptamine receptors in GtoPdb v.2023.1
Andrade, R., Barnes, N. M., Baxter, G., Bockaert, J., Branchek, T. A., Butler, A. S., Cohen, M. L., Dumuis, A., Eglen, R. M., Göthert, M., et al. (2023) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f1/2023.1 · Cited by 3
Vaiana, A. M., Asher, A. M., Tapia, K., & Morilak, D. A. (2023) · Neuroendocrinology · doi:10.1159/000535365 · Cited by 3
“In addition to blocking the serotonin transporter, vortioxetine acts at multiple pre-and post-synaptic serotonin receptors [16], which are thought to contribute to its unique effects on cognition.”
BackgroundPharmacogenomics in Psychiatric Diseases
Kekić, A. (2023) · Springer eBooks · doi:10.1007/978-3-031-45903-0_9 · Cited by 3
Lopez-Munoz, F. J., D’Ocón, P., Romero, A., Berardis, D. D., & Álamo, C. (2025) · ALPHA PSYCHIATRY · doi:10.31083/ap40037 · Cited by 4
“Additionally, vortioxetine exhibits significant affinity for DA and NA transporters, being 3 to 12 times more selective for 5-HT transporters, respectively [67].”
Hochstrasser, B., Hasler, G., Baumann, A., Bose, R., Reines, E. H., Kammerer, M. H., & Sousek, A. (2025) · CNS Drugs · doi:10.1007/s40263-025-01207-2 · Cited by 3
“Vortioxetine is an antidepressant with multimodal activity in the central nervous system [9–11], which is approved for the treatment of major depressive episodes in adults [11, 12].”
Roman, M. W., & Wilkinson, S. M. (2014) · Issues in Mental Health Nursing · doi:10.3109/01612840.2014.955155 · Cited by 3
“The in vivo studies confirm this action with evidence of heightened levels of serotonin, noradrenaline, and acetylcholine, as well as dopamine and histamine in the ventral hippocampus and the median prefrontal cortex (Bang-Anderson et al., 2011).”
BackgroundJacobsen, P. L., Zhong, W., Xu, R., & Nomikos, G. G. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.090 · Cited by 3
Inoue, T., Fujimoto, S., Marumoto, T., Kitagawa, T., Ishida, K., Nakajima, T., Moriguchi, Y., Fujikawa, K., & Watanabe, K. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s335028 · Cited by 3
“Vortioxetine was developed as a serotonin reuptake inhibitor and modulator based on the hypothesis that combining 5-HT3/5-HT1A receptor antagonism with SERT inhibition could have therapeutic potential for both depressed mood and anxiety.(11) Through these combined mechanisms, it has been postulated that vortioxetine e…”
BackgroundOdagaki, Y., Mikami, M., Kinoshita, M., Meana, J. J., Callado, L. F., García-Sevilla, J. A., Borroto‐Escuela, D. O., & Fuxé, K. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00448-6 · Cited by 2
“These drugs include aripiprazole [22–25], brexpiprazole [25], lurasidone [26], asenapine [27], and vortioxetine [28, 29], and their abilities to stimulate 5-HT1A receptor have been compared in the same experimental system in the present study.”
BackgroundChokka, P. R., Hammer-Helmich, L., Schmidt, S. N., Hubert, M., Reines, E. H., & Grande, I. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2503976 · Cited by 2
“Vortioxetine is a multimodal antidepressant that was designed to combine 5-HT 3 receptor antagonism, 5-HT 1A receptor agonism, and serotonin transporter inhibition to modulate neurotransmission beyond that of selective serotonin reuptake inhibitors (SSRIs) 30,31 .”
Anticholinergic Equivalence in Psychotropic Medications
Badre, N., & Geier, E. T. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002073 · Cited by 2
Sałaciak, K., Lustyk, K., Jagielska, A., Szafarz, M., Inteiro-Oliveira, S., Diógenes, M. J., Xapelli, S., Schnur, P., Morton, L., Moran, E., et al. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00774 · Cited by 5
“…is a multimodal antidepressant acting as a 5-HT 1A receptor agonist and 5-HT 3 /5-HT 7 receptor antagonist with serotonin transporter inhibition [65], whereas lurasidone is an atypical antipsychotic combining D 2 and 5-HT 2A receptor antagonism with 5-HT 7 blockade [66] - mechanisms associated…”
Neurobiological Aspects of Functional Recovery in Major Depressive Disorder
Chakrabarty, T., Sarfati, D., & Lam, R. W. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813333-0.00024-x · Cited by 2
Bröer, S., & Rudnick, G. (2019) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f144/2019.4 · Cited by 2
Bortoletto, R., Puttini, E., Zoccante, L., & Colizzi, M. (2021) · Reports — Medical Cases Images and Videos · doi:10.3390/reports4040030 · Cited by 2
“It is thought to modulate several neurotransmitters, including histamine, norepinephrine, acetylcholine, glutamate, and γ-aminobutyric acid (GABA) [6,7].”
BackgroundLadefoged, L. K., Koch, R., Biggin, P. C., & Schiøtt, B. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00029 · Cited by 2
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.017 · Cited by 2
SLC6 neurotransmitter transporter family in GtoPdb v.2023.1
Bröer, S., & Rudnick, G. (2023) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f144/2023.1 · Cited by 3
NeuropsychopharmARCology: Shaping Neuroplasticity through Arc/ Arg3.1 Modulation
Mottarlini, F., Caffino, L., Fumagalli, F., Calabrese, F., & Brivio, P. (2024) · Current Neuropharmacology · doi:10.2174/011570159x338335240903075655 · Cited by 3
“Vortioxetine is a novel multimodal AD that combines different features as it is a 5-HT 1A receptor agonist, a 5-HT 1B receptor partial agonist, an antagonist for 5-HT 3 , 5-HT 7 , 5-HT 1D receptors, and a serotonin transporter inhibitor [106].”
LIGANDY RECEPTORA 5-HT1A JAKO POTENCJALNE LEKI PRZECIWDEPRESYJNE
Wróbel, M. Z., & Marciniak, M. (2015) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.115 · Cited by 2
Caraci, F., & Sciascio, G. D. (2015) · Cited by 2
Clinical Need and Rationale for Multi-Target Drugs in Psychiatry
Shahid, M. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734912-00014 · Cited by 2
Clinical relevance of cognitive dysfunction in major depressive disorder
Cha, D. S. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781139860567.002 · Cited by 2
Bundgaard, C., Pehrson, A. L., Sánchez, C., & Bang‐Andersen, B. (2015) · Wiley eBooks · doi:10.1002/9781118788523.ch23 · Cited by 2
Self-citationVortioxetine: a comprehensive update on a new-generation antidepressant
Evren, C. (2021) · Dusunen Adam The Journal of Psychiatry and Neurological Sciences · doi:10.14744/dajpns.2021.00115 · Cited by 2
“Vortioxetine is largely metabolized trough oxidation and is a substrate for many CYP450 isoforms, primarily cytochrome P450 (CYP450) and 2D6 (CYP2D6) (14,17).”
BackgroundInfluentialStahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.024 · Cited by 2
Ardau, R., Carta, P., Chillotti, C., Deiana, V., Del Zompo, M., Manchia, M., & Bocchetta, A. (2012) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2012.736163 · Cited by 2
Nomikos, G. G. (2019) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-803161-2.00027-8 · Cited by 1
Li, Q., Ren, L., Wang, D., Luo, J., Xu, C., Feng, J., Qiu, Y., Xu, X., & Chen, G. (2024) · Molecules · doi:10.3390/molecules29225240 · Cited by 1
“These drugs work by elevating the levels of serotonin in the synaptic cleft, thereby enhancing its availability for neurotransmission [5].”
DGAT‐1 deficiency: Congenital diarrhea and dietary treatment
Gardemann, C., Och, U., Fobker, M., Kaiser, T., Horvath, J. E., Prada, B. D., & Marquardt, T. (2025) · JPGN Reports · doi:10.1002/jpr3.70016 · Cited by 2
Sahoo, S., & Rit, A. (2025) · Angewandte Chemie · doi:10.1002/ange.202504156 · Cited by 1
Guan, L., Feng, D., Ge, J., Qi, B., Sun, Y., & Zou, Y. F. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c01240 · Cited by 1
Queder, J., & Hilt, G. (2025) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.70116 · Cited by 1
Zheng, J., Tian, Y., Cheng, J., Hu, Z., Zhang, J., Yang, F., Li, P., Jiang, Z., Gong, X., Hou, Q., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118198 · Cited by 1
Effects of Short- and Long-Term Vortioxetine Administration on Reproductive Function in Female Rats
Bingul, E., Hizal, E., Keles, O., Yucel, N., Süleyman, Z., Günay, M., Yaşar, H., & Süleyman, H. (2025) · Pharmaceuticals · doi:10.3390/ph18111690 · Cited by 1
“This regimen yields plasma levels analogous to those observed in patients treated with 10–20 mg/day vortioxetine [3,4], supporting translational comparability.”
Inoue, T., OTAKE, R., & Hoshino, T. (2025) · Neuropsychopharmacology Reports · doi:10.1002/npr2.70077 · Cited by 1
One-Pot Synthesis of Nitriles from Aldehydes Enabled by Amino-λ 3 -iodane
Xiao, D., He, J., Yang, K., Wang, Z., Feng, L., Zhang, W., & Du, Y. (2026) · Organic Letters · doi:10.1021/acs.orglett.6c01387 · Cited by 1
The Stability Study of a Novel Phenylpiperazine Derivative
Tarsa, M., Starek, M., Dąbrowska, M., Baran, M., Czarny, A., & Cegla, M. T. (2019) · Modern Organic Chemistry Research · doi:10.22606/mocr.2019.41001 · Cited by 1
On the Basicity of 8-Phenylsulfanyl Quipazine Derivatives: New Potential Serotonergic Agents
Pieńko, T., Taciak, P., & Mazurek, A. P. (2015) · The Journal of Physical Chemistry A · doi:10.1021/acs.jpca.5b02908 · Cited by 1
Vortioxetine in major depressive disorder: a guide to its use in the EU
Garnock-Jones, K. P., & Lyseng-Williamson, K. A. (2015) · Drugs & Therapy Perspectives · doi:10.1007/s40267-015-0217-x · Cited by 1
“Vortioxetine binds to human SERT with high affinity and potently and selectively inhibits serotonin reuptake [4, 5]; it has a much lower affinity for the human norepinephrine and dopamine transporters [4].”
BackgroundWeatherspoon, D. L., Weatherspoon, C. A., & Abbott, B. (2015) · Nursing Clinics of North America · doi:10.1016/j.cnur.2015.07.006 · Cited by 1
Novel and Investigational Drugs in Depression
Shapiro, D. N., & Stahl, S. M. (2014) · International Neuropsychiatric Disease Journal · doi:10.9734/indj/2014/11590 · Cited by 1
“Vortioxetine exerts 5-HT1D, 5-HT3, and 5-HT7 antagonism, 5-HT1B receptor partial agonism, 5-HT1A agonism, and SERT inhibition [4,16-17].”
BackgroundNew antidepressant drugs for new depressions.
Juli, A., & Juli, L. (2014) · PubMed · Cited by 1
Vortioxetine – an antidepressant with a multifunctional mechanism of action
Wysokiński, A., & Sobów, T. (2016) · Psychiatria i Psychologia Kliniczna · doi:10.15557/pipk.2016.0014 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.083 · Cited by 1
Finley, P. R., Lê, J., & Lee, K. C. (2016) · Springer eBooks · doi:10.1007/978-3-319-27883-4_9 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.045 · Cited by 2
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.018 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.032 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.086 · Cited by 1
Metadata
- Authors
- Bang-Andersen, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G., Zhong, H., Nielsen, S. M., Hogg, S., Mørk, A., & Stensbøl, T. B.
- Affiliations
- Neuroscience Drug Discovery Denmark, H. Lundbeck A/S, 9 Ottiliavej, DK-2500 Copenhagen-Valby, Denmark
- Lundbeck (Denmark) (DK)
- Lundbeck (United States) (US)
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2011-04-12
- Volume
- 54
- Issue
- 9
- Pages
- 3206-3221
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2036812642
- Cited by
- 606
- References
- 58
- Citations by year
- 2026: 20 · 2025: 26 · 2024: 24 · 2023: 33 · 2022: 27 · 2021: 27 · 2020: 181 · 2019: 32 · 2018: 21 · 2017: 37 · 2016: 37 · 2015: 53 · 2014: 35 · 2013: 25 · 2012: 21
- FWCI
- 21.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- vortioxetine, major depressive disorder, multimodal antidepressant, 5-HT3 receptor antagonists, 5-HT1A receptor, 5-HT1B receptor, 5-HT7 receptor, serotonin transporter inhibition, structure-activity relationship, piperazine derivatives
- MeSH terms
- Vortioxetine, Animals, Antidepressive Agents, Cell Line, Major Depressive Disorder, Depressive Disorder, Major, Drug Stability, Hippocampus, Humans, Microsomes, Liver, Oocytes, Piperazines, Radioligand Assay, Receptors, Serotonin, Recombinant Proteins, Serotonin, Structure-Activity Relationship, Sulfides, Xenopus, Selective Serotonin Reuptake Inhibitors, Receptors, Serotonin, 5-HT1, Receptor, Serotonin, 5-HT1A, Receptor, Serotonin, 5-HT2C, Receptors, Serotonin, 5-HT3, Serotonin Plasma Membrane Transport Proteins, Rats, Drug Partial Agonism, Serotonin 5-HT1 Receptor Agonists, Serotonin 5-HT3 Receptor Antagonists, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.